BioCentury
ARTICLE | Company News

BioLineRx, Ben-Gurion University, Hadassah University Hospitals, The Hebrew University of Jerusalem deal

October 28, 2013 7:00 AM UTC

The technology transfer arms of the universities granted BioLineRx exclusive, worldwide rights to BL-9020, a mAb inhibitor of natural cytotoxicity triggering receptor 1 ( NCR1; NKP46; CD335), to t...